TABLE 4.

Receiver operating characteristic curve analysis of PBE, ALOX15, CLC, CYSLTR2, HRH4 and SMPD3

	Healthy controls versus				Asthma versus	Asthma +CRSwNP versus
	Total	Asthma	Asthma +CRSwNP	N-ERD	Asthma +CRSwNP	N-ERD
PBE	0.95 (0.92–0.98)	0.94 (0.90–0.98)	0.97 (0.94–1.00)	0.97 (0.94–1.00)	0.68 (0.57–0.81)	0.45* (0.29–0.62)
ALOX15	0.93 (0.90–0.97)	0.93 (0.89–0.98)	0.96 (0.92–1.00)	0.91 (0.83–0.98)	0.57* (0.45–0.71)	0.38* (0.22–0.54)
CLC	0.86* (0.80–0.91)	0.79* (0.70–0.87)	0.93 (0.88–0.99)	0.93 (0.86–1.00)	0.66 (0.55–0.78)	0.63 (0.46–0.81)
CYSLTR2	0.92 (0.88–0.96)	0.91 (0.85–0.96)	0.93 (0.87–0.99)	0.93 (0.86–1.00)	0.57* (0.44–0.70)	0.53 (0.36–0.70)
HRH4	0.85* (0.79–0.91)	0.78* (0.70–0.87)	0.95 (0.90–1.00)	0.88* (0.79–0.97)	0.72 (0.61–0.83)	0.44* (0.26–0.61)
SMPD3	0.91 (0.87–0.95)	0.88 (0.82–0.94)	0.95 (0.91–1.00)	0.91 (0.84–0.98)	0.62 (0.50–0.75)	0.42* (0.25–0.60)

Data are presented as the area under the receiver operating characteristic curve (AUC) (95% confidence interval). For each patient group (columns), yellow shading indicates the highest absolute value of the AUC; grey shaded cells indicate the AUC is significantly lower than the highest AUC value; in all other cells, the AUC values are statistically equivalent (p>0.05) to the highest AUC value; CRSwNP: chronic rhinosinusitis with nasal polyposis; N-ERD: nonsteroidal anti-inflammatory drug-exacerbated respiratory disease; PBE: peripheral blood eosinophils. *: p<0.05.